Procyon Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.23 Cr
- Revenue Growth -41.77%
- Profit Growth -31.83%
- Ebitda -39.66%
- Net Worth 20.84%
- Total Assets -17.83%
About Procyon Life Sciences
Procyon Life Sciences Private Limited (PLSPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 November 2006 and has a history of 18 years and three months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹2.23 Cr.
Seema Dharamshi, Ajay Virchand, and Rajveer Dharamshi serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24239MH2006PTC165479
- Company No.
165479
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Nov 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Procyon Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Virchand  | Managing Director | 10-Nov-2006 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Seema Dharamshi | Director | 10-Nov-2006 | Current |
| Rajveer Dharamshi | Director | 01-Feb-2022 | Current |
Financial Performance of Procyon Life Sciences.
Procyon Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 41.77% decrease. The company also saw a substantial fall in profitability, with a 31.83% decrease in profit. The company's net worth Soared by an impressive increase of 20.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Procyon Life Sciences?
In 2023, Procyon Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹22.30 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.23 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Dec 2017 | Others | ₹2.23 Cr | Open |
How Many Employees Work at Procyon Life Sciences?
Unlock and access historical data on people associated with Procyon Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Procyon Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Procyon Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
